ACA Subsidies Expired. Open Enrollment Ended. But It Will Still Take Awhile To Register the Results.

It’s February, so open enrollment for the Affordable Care Act is over. We’re getting the first glimpses of how sign-ups are shaking out after the expiration of enhanced subsidies that helped most people with their premium costs.  While more Americans enrolled than some policy analysts had expected, the number was still 1.2 million below what it was at the same time last year. And experts say it will be months until the numbers are final. The timing will depend on how many of those people who…

Read More

Friday Links

Expert opinions: Will MFN reduce US drug prices?Robots in maternity care.What drives company decisions on new medicine launches and UK investment?Incorporating dynamic pricing into HEOR models (dynamicpv)Tale of 2 value sets.How to handle the lows? Honesty.Integrity in journalism: Giannis edition.

Read More

Amodei Believes “AI-Enabled Autocracy” Could Be Imminent

By MIKE MAGEE Last month, Dario Amodei, CEO of Anthropic, did it again – scaring the bejesus out of societal leaders worldwide with warnings that their grip on security and governance of human populations is dangerously close to AI extinction. Amodei’s opening paragraph in his article titled “The Adolescence of Technology” wastes no time getting the reader’s…

Read More

Addressing the translational research gap

In a recent report, the Association of the British Pharmaceutical Industry (ABPI) examines the UK’s “translational readiness gap”—the persistent failure to move cutting-edge laboratory models into the actual creation of medicines to treat patients. The Attrition Problem and the Translational Gap Modern drug development is a high risk endeavor. Approximately 90% of drug candidates that…

Read More